<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:bovine-ojs-tamu.tdl.org:article/3199</identifier>
				<datestamp>2020-04-09T16:31:01Z</datestamp>
				<setSpec>aabp:Post</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A comparison of three feedlot vaccination programs on the health, growth performance, and carcass characteristics of high-risk heifers procured from auction markets</dc:title>
	<dc:creator xml:lang="en">Hagenmaier, J. A.</dc:creator>
	<dc:creator xml:lang="en">Terhaar, B. L.</dc:creator>
	<dc:creator xml:lang="en">Blue, K.</dc:creator>
	<dc:creator xml:lang="en">Hoffman, B. W.</dc:creator>
	<dc:creator xml:lang="en">Fox, J. T.</dc:creator>
	<dc:creator xml:lang="en">Theurer, M. E.</dc:creator>
	<dc:subject xml:lang="en">bovine respiratory disease</dc:subject>
	<dc:subject xml:lang="en">BRD</dc:subject>
	<dc:subject xml:lang="en">vaccines</dc:subject>
	<dc:subject xml:lang="en">pathogen</dc:subject>
	<dc:subject xml:lang="en">antigens</dc:subject>
	<dc:subject xml:lang="en">health</dc:subject>
	<dc:subject xml:lang="en">growth performance</dc:subject>
	<dc:subject xml:lang="en">feedlot cattle</dc:subject>
	<dc:description xml:lang="en">Mannheimia haemolytica (MH) is the primary bacterium involved with bovine respiratory disease (BRO), and there are differences between how the vaccines which confer immunity against this important pathogen are manufactured. Generally speaking, the bacterin and toxoid components of commercially available MH vaccines are harvested through propagation of whole-cell MH cultures. NupluraÂ® PH (NUP; Elanco Animal Health, Greenfield, IN) contains both toxoid and cell-associated antigens, but these antigens differ as they are manufactured using recombinant technology and a proprietary purification process. The relative efficacy of vaccine programs incorporating NUP versus products derived from whole-cell MH culture has not been evaluated in a large-pen feedlot setting. The objective of this study was to compare 3 vaccination programs on the health, growth performance, and carcass characteristics of feedlot heifers.</dc:description>
	<dc:publisher xml:lang="en">American Association of Bovine Practitioners</dc:publisher>
	<dc:date>2018-09-13</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://bovine-ojs-tamu.tdl.org/aabp/article/view/3199</dc:identifier>
	<dc:identifier>10.21423/aabppro20183199</dc:identifier>
	<dc:source xml:lang="en">American Association of Bovine Practitioners  Conference Proceedings; 2018; 322</dc:source>
	<dc:source>1079-9737</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://bovine-ojs-tamu.tdl.org/aabp/article/view/3199/3168</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2018 American Association of Bovine Practitioners</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
